Switzerland· 57674015
Levacin 200/50, Retardtabletten
A levodopa und decarboxylasehemmer product containing carbidopum, levodopum, registered in Switzerland by Acino Pharma AG and dispensed under Swissmedic category B. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Levodopa und decarboxylasehemmer is registered in 12 of 19 countries.
Countries holding a registration under ATC N04BA02 (levodopa und decarboxylasehemmer), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Levodopa und decarboxylasehemmer · ATC N04BA02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- carbidopum, levodopum
- Manufacturer
- Acino Pharma AG
- Country
- Switzerland (CH)
- ATC code
- N04BA02
- ATC class
- Levodopa und Decarboxylasehemmer
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
158 interactions on record for levodopa und decarboxylasehemmer.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Levodopa und decarboxylasehemmer · interactions on record
158 records
- 4 severe
- 122 moderate
- 14 minor
Most severe, free to view
- ProcarbazineL01XB01severe
- OzanimodL04AA38severe
- OzanimodL04AE02severe
- Methylthioninium chlorideV03AB17severe
18 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N04BA02
Levodopa und decarboxylasehemmer, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cfa9be4b-7d50-400f-ab26-6b5051a48e35 GET /v1/drugs/cfa9be4b-7d50-400f-ab26-6b5051a48e35?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about levodopa und decarboxylasehemmer.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.